Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10455390 | 0.74 | TSHR (0.50) | CARM1MEN1KMT2A | |
| SCHEMBL29428684 | 0.73 | BCL2L1 (0.56) | CARM1MEN1KMT2A | |
| SCHEMBL1513686 | 0.73 | BCL2L1 (0.50) | CARM1ABHD6MEN1KMT2A | |
| SCHEMBL29459963 | 0.73 | BCL2L1 (0.50) | CARM1ABHD6MEN1KMT2A | |
| SCHEMBL1513618 | 0.73 | BCL2L1 (0.56) | CARM1MEN1KMT2A | |
| SCHEMBL16076617 | 0.71 | MAOA (0.57) | CARM1ABHD6AKR1C3PRMT6PRMT1 | |
| SCHEMBL13464088 | 0.71 | ABHD6 (0.47) | CARM1ABHD6AKR1C3PRMT6PRMT1 | |
| SCHEMBL19643944 | 0.71 | CARM1 (0.42) | CARM1ABHD6AKR1C3PRMT6PRMT1 | |
| SCHEMBL3976079 | 0.68 | — | — | |
| SCHEMBL4006320 | 0.68 | ABHD6 (0.47) | CARM1ABHD6AKR1C3PRMT6PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | CARM1 1821/4885ABHD6 3093/4885AKR1C3 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.